MedMira Ships 400,000 Tests to China and Receives Follow-on Order
Halifax, Nova Scotia, July 13, 2011 – MedMira Inc., (“MedMira”) (TSX Venture: MIR) (NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, today announced that it has completed and shipped the order for 400,000 rapid HIV tests placed by its strategic partner in China, Triplex International Biosciences Co., Ltd. (Triplex), in April 2011.
“The fulfillment of this initial order for Triplex went very smoothly,” said Hermes Chan, CEO, MedMira Inc. “The Triplex sales strategy in the new China healthcare sector is working very well, with the number one ranking of our test in a recent evaluation by the China National Center for Disease Control (China CDC) being a key marketing tool in many of their initiatives."
Triplex has placed a follow-on order for MedMira rapid HIV tests as it continues to pursue sales opportunities in the outreach clinics and hospital laboratory vertical markets in the high growth rapid diagnostics market within China’s restructured healthcare system.
“We are very pleased with the sales progress our business development team is making with the MedMira rapid HIV test,” said Yiu Ming Fung, President and Chairman of Triplex International Biosciences Co., Ltd. “The MedMira product has been a great addition to our product portfolio. The test is achieving excellent results in evaluations and customers are very pleased with the speed, quality and performance.”
About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics and technologies. The Company’s tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis of infectious diseases. MedMira diagnostics are sold under the Reveal®, MiraWell®, Multiplo™, and Miriad brands in global markets. MedMira’s rapid HIV test is the only rapid HIV test in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira’s website at www.medmira.com.
This news release contains forward-looking statements, including statements regarding development of sales opportunities, which involve risk and uncertainties and reflect the company’s current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
MedMira Contact:
Andrea Young
T. 902-450-1588
E. ayoung@medmira.com
